Your browser doesn't support javascript.
loading
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.
Casaletto, Jessica B; Geddie, Melissa L; Abu-Yousif, Adnan O; Masson, Kristina; Fulgham, Aaron; Boudot, Antoine; Maiwald, Tim; Kearns, Jeffrey D; Kohli, Neeraj; Su, Stephen; Razlog, Maja; Raue, Andreas; Kalra, Ashish; Håkansson, Maria; Logan, Derek T; Welin, Martin; Chattopadhyay, Shrikanta; Harms, Brian D; Nielsen, Ulrik B; Schoeberl, Birgit; Lugovskoy, Alexey A; MacBeath, Gavin.
Afiliação
  • Casaletto JB; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Geddie ML; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Abu-Yousif AO; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Masson K; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Fulgham A; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Boudot A; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Maiwald T; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Kearns JD; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Kohli N; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Su S; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Razlog M; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Raue A; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139; araue@merrimack.com gavin.macbeath@gmail.com.
  • Kalra A; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Håkansson M; SARomics Biostructures AB, Medicon Village, SE-223 81 Lund, Sweden.
  • Logan DT; SARomics Biostructures AB, Medicon Village, SE-223 81 Lund, Sweden.
  • Welin M; SARomics Biostructures AB, Medicon Village, SE-223 81 Lund, Sweden.
  • Chattopadhyay S; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Harms BD; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Nielsen UB; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Schoeberl B; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • Lugovskoy AA; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.
  • MacBeath G; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139; araue@merrimack.com gavin.macbeath@gmail.com.
Proc Natl Acad Sci U S A ; 116(15): 7533-7542, 2019 04 09.
Article em En | MEDLINE | ID: mdl-30898885
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transdução de Sinais / Fator de Crescimento de Hepatócito / Anticorpos Biespecíficos / Proteínas Proto-Oncogênicas c-met / Molécula de Adesão da Célula Epitelial / Antineoplásicos Imunológicos / Neoplasias Experimentais Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transdução de Sinais / Fator de Crescimento de Hepatócito / Anticorpos Biespecíficos / Proteínas Proto-Oncogênicas c-met / Molécula de Adesão da Célula Epitelial / Antineoplásicos Imunológicos / Neoplasias Experimentais Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2019 Tipo de documento: Article